Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilengitide in recurrent glioblastoma multiforme
NCT00093964Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Oct 2004
- Primary completion
- Oct 2005
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cilengitide in glioblastoma multiforme (GBM) (2 arms), sponsored by EMD Serono. Primary endpoint: Progression-free Survival at 6 months. Started Oct 2004; status: completed.
02
Drugs
cilengitide
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00093964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093964.